1. Home
  2. Vol 49, No 4 (2017)
  3. Bawazier

Current and Emerging Therapy on Lupus Nephritis

Lucky Aziza Bawazier

Abstract


Lupus nephritis (LN) is involvement of the kidney in patient with systemic lupus erythematosus (SLE) and one of the most common target organ in SLE. The diagnosis of LN will significantly impact the clinical outcome and therapy of the patient. Therapy regiment of LN is divided into two stages, induction and maintenance treatment. The main objective of the induction therapy is to achieve complete or partial remission as soon as possible since it is correlated with better prognosis and fewer relapse incidence. In the maintenance stage, the main aim of the therapy is to maintain the remission status and avoid future relapse. It is also important to evaluate the effectiveness of the therapy as it will affect the duration and the regiment therapy being used. Corticosteroid, cyclophosphamide, mycophenolate mofetil, azathrioprine, cyclosporine and tacrolimus are example of drugs used in LN therapy. Currently, studies are being conducted to evaluate and develop targeted drug therapy to further add treatment options for LN.

Keywords


Systemic lupus erythematosus; lupus nephritis; kidney

References


Patel M, Clarke AM, Bruce IN, Symmons DP. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheumatol. 2006;54(9):2963-9.

Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12(2):174–94.

Yap D, Tang C, Ma M, Lam M, Chan T. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27(8):3248-54.

Bomback SA, Appel GB. Updates on the treatment of lupus nephritis. JASN. 2010;21(12):2028-35.

Pramono LA, Karim B, Rajabto W, Siregar P, Sukmana N, Setyohadi B. Mycophenolate mofetil versuscyclosphophamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses. Med J Indones. 2012;21:44-51.

Lanz O, Waheed AA, Baig A, Pop A, Contreras G. Lupus nephritis: maintenance therapy for lupus nephritis-do we now have a plan?. CJASN. 2013;8(1):162-71.

Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH. Therapy of lupus nephritis. controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614-9.

Appel GB. New and future therapies for lupus nephritis. CCJM. 2012;79(2):134-40.

Ginzler EM, Dooley MA, Arranow C, et al. Mycophenolate mofetil or intravenous cyclosphophamide for lupus nephritis. N Engl J Med. 2005;353:2219-28.

Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2004;350:971-80.

Appel GB, Contreras G, Doole MA, et al. Mycophenolate mofetil versus cyclosphophamide for induction of lupus nephritis. JASN. 2009;20(5):1103-12.

Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152-60.

Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis. Ann Intern Med. 2015;162:18-26.

Bao H, Liu ZH, Zie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001-10.

Ikeuchi H, Hiromura K, Takahashi S, et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24(4):618-25.

Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis. 2017;70(3):324-36.

Kidney Disease Improving Global Outcomes (KDIGO), KDIGO Clinical Practice Guideline for Glomerulonephritis. 2012. Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf [Accessed 22nd November 2017].

Irastorza GR, Espinosa G, Frutos MA, et al. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine and the Spanish Society of Nephrology (S.E.N.). Nefrolgia. 2012;32(1):1-35.

Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797-909.

Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2016; doi:10.2215/CJN.05780616.

Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. Arthritis Rheumatism. 2012;64(4):1215-26.

Eknoyan G, Lameire N, Eckardt K, et al. KDIGO clinical practice for glomerulonephritis. Kidney Intl Suppl. 2012;2(2):221-32.

Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and and European Renal Association—European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771-82.

Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886-95.

Houssiau FA, Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis. 2010;69:2083-9.

Ruiz IG, Espinosa G, Frutos MA. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia. 2012;32(1):1-35.

Arends S, Grootscholten C, Derksen RH, Berger SP, de Sevaux RG. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2012;71(6):966-73.

Tellingen AV, Voskuyl AE, Vervloet MG, et al. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Netherlands J Med. 2012;70(4):199-206.

Corapi KM, Dooley MA, Pendergraft WF. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res and Ther. 2015;17:110.

Haladyj E, Cervera R. Do we still renal biopsy in lupus nephritis? Reumatologia. 2016;54(2):61-6.

Ronbloom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23:113-21.

Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammaco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008;58:251-62.

Rovin BH, Furie R, Latinis K, et al. LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with Rituximab study. Arthritis Rheum. 2012;64:1215-26.

Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis guidelines and perspective from Asia. Nephrol. 2014; doi:10.1111.

Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.

Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Lupus nephritis collaborative study group: long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol. 1996;7:299-305.

Dooley MA, Houssiau F, Aranow C, et al. BLISS-52 and -76 Study Group: Effect of belimumab treatment on renal oucomes in patients with SLE. Lupus. 2013;22:63-72.

Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Eng J Med. 2014;370:1101-10.

Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393-02.

Rovin BH, Dooley MA, Radhakrishnan J, et al. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from phase 3 clinical trials. Lupus. doi: 10.11177/0961203316650734.

Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjorgen’s syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis. 2013;72:146-8.

Cheng Q, Mumtaz IM, Khodadadi L, et al. Autoantibodies from long-lived memory plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis. 2013;72:2011-7.

Espeli M, Boekrs S, Giannco G, et al. Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol. 2011;22:296-305.

Hiepe F, Domer T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7:170-8.

Furie R, Merrill JT, Werth VT, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody in moderate to severe systemic lupus erythematosus. Am Coll Rheumatol. 2015.

Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013;148:313-21.

Glikeson GS. Complement targeted therapies in lupus. Current Treat Options Rheum. 2015;1:10-18.

Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25:225-31.


Full Text: PDF

Refbacks

  • There are currently no refbacks.